Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 6, 2010, Pages 2727-2735

  Fabbrini, Elisa ^a,b   Mohammed, B Selma ^a   Korenblat, Kevin M ^a   Magkos, Faidon ^c   McCrea, Jennifer ^a   Patterson, Bruce W ^a   Klein, Samuel ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Instituto di Ricovero e Cura a Carattere Scientifico   (Italy)

^c HAROKOPIO UNIVERSITY   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; FENOFIBRATE; INSULIN; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID; PLACEBO; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; ANTILIPEMIC AGENT; FATTY ACID;

ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; INSULIN RESPONSE; INSULIN SENSITIVITY; LIPID LIVER LEVEL; LIPOPROTEIN METABOLISM; MALE; NONALCOHOLIC FATTY LIVER; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ADULT; BLOOD; BODY COMPOSITION; FATTY LIVER; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; INSULIN RESISTANCE; KINETICS; LIVER; METABOLISM; MIDDLE AGED; PHYSIOLOGY; RISK FACTOR;

ADULT; ANTILIPEMIC AGENTS; APOLIPOPROTEINS B; BLOOD GLUCOSE; BODY COMPOSITION; DOUBLE-BLIND METHOD; FATTY ACIDS, NONESTERIFIED; FATTY LIVER; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMANS; INSULIN; INSULIN RESISTANCE; KINETICS; LIPOPROTEINS, VLDL; LIVER; MALE; MIDDLE AGED; NIACIN; OBESITY; PROCETOFEN; RISK FACTORS; TRIGLYCERIDES;

EID: 77954519409     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-2622     Document Type: Article

References (51)

1. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N 2001 Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50:1844-1850
2. Westerbacka J, Cornér A, Tiikkainen M, Tamminen M, Vehkavaara S, Häkkinen AM, Fredriksson J, Yki-Järvinen H 2004 Women and men have similar amounts of liver and intraabdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk. Diabetologia 47:1360-1369
3. Targher G, Arcaro G 2007 Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 191: 235-240 (Pubitemid 46400718)
4. Ruttmann E, Brant LJ, Concin H, Diem G, Rapp K, Ulmer H 2005 γ-Glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults. Circulation 112:2130-2137
5. Targher G, Bertolini L, Poli F, Rodella S, Scala L, Tessari R, Zenari L, Falezza G 2005 Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 54: 3541-3546
6. Gulick T, Cresci S, Caira T, Moore DD, Kelly DP 1994 The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. Proc Natl Acad Sci USA 91:11012-11016
7. Harano Y, Yasui K, Toyama T, Nakajima T, Mitsuyoshi H, Mimani M, Hirasawa T, Itoh Y, Okanoue T 2006 Fenofibrate, a peroxisome proliferator-activated receptor α agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver. Liver Int 26:613-620 (Pubitemid 43757124)
8. Hong XZ, Li LD, Wu LM 2007 Effects of fenofibrate and xuezhikang on high-fat diet-induced non-alcoholic fatty liver disease. Clin Exp Pharmacol Physiol 34:27-35
9. Lewis GF, Uffelman KD, Szeto LW, Weller B, Steiner G 1995 Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J Clin Invest 95:158-166
10. Wang W, Basinger A, Neese RA, Shane B, Myong SA, Christiansen M, Hellerstein MK 2001 Effect of nicotinic acid administration on hepatic very low density lipoprotein-triglyceride production. Am J Physiol Endocrinol Metab 280:E540-E547
11. Korenblat KM, Fabbrini E, Mohammed BS, Klein S 2008 Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. Gastroenterology 134: 1369-1375
12. Fabbrini E, Mohammed BS, Magkos F, Korenblat KM, Patterson BW, Klein S 2008 Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology 134:424-431
13. Wang W, Basinger A, Neese RA, Christiansen M, Hellerstein MK 2000 Effects of nicotinic acid on fatty acid kinetics, fuel selection, and pathways of glucose production in women. Am J Physiol Endocrinol Metab 279:E50-E59 (Pubitemid 30609944)
14. Kahn SE, Beard JC, Schwartz MW, Ward WK, Ding HL, Bergman RN, Taborsky Jr GJ, Porte Jr D 1989 Increased β-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance. Diabetes 38:562-568
15. Chang AM, Smith MJ, Galecki AT, Bloem CJ, Halter JB 2006 Impaired β-cell function in human aging: response to nicotinic acidinduced insulin resistance. J Clin Endocrinol Metab 91:3303-3309
16. Vega GL, Cater NB, Meguro S, Grundy SM 2005 Influence of extended-release nicotinic acid on nonesterified fatty acid flux in the metabolic syndrome with atherogenic dyslipidemia. Am J Cardiol 95:1309-1313
17. Grundy SM, Vega GL, McGovern ME, Tulloch BR, Kendall DM, Fitz-Patrick D, Ganda OP, Rosenson RS, Buse JB, Robertson DD, Sheehan JP 2002 Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med 162:1568-1576
18. Mittendorfer B, Patterson BW, Klein S 2003 Effect of weight loss on VLDL-triglyceride and apoB-100 kinetics in women with abdominal obesity. Am J Physiol Endocrinol Metab 284:E549-E556 (Pubitemid 36237543)
19. Patterson BW, Zhao G, Elias N, Hachey DL, Klein S 1999 Validation of a new procedure to determine plasma fatty acid concentration and isotopic enrichment. J Lipid Res 40:2118-2124 (Pubitemid 29523438)
20. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC 1985 Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419
21. Bugianesi E, Gastaldelli A, Vanni E, Gambino R, Cassader M, Baldi S, Ponti V, Pagano G, Ferrannini E, Rizzetto M 2005 Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 48:634-642
22. Seppälä-Lindroos A, Vehkavaara S, Häkkinen AM, Goto T, Westerbacka J, Sovijärvi A, Halavaara J, Yki-Järvinen H 2002 Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 87:3023-3028
23. Guerre-Millo M, Gervois P, RaspéE, Madsen L, Poulain P, Derudas B, Herbert JM, Winegar DA, Willson TM, Fruchart JC, Berge RK, Staels B 2000 Peroxisome proliferator-activated receptor α activators improve insulin sensitivity and reduce adiposity. J Biol Chem 275:16638-16642
24. Kim H, Haluzik M, Asghar Z, Yau D, Joseph JW, Fernandez AM, Reitman ML, Yakar S, Stannard B, Heron-Milhavet L, Wheeler MB, LeRoith D 2003 Peroxisome proliferator-activated receptor-α agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis. Diabetes 52:1770-1778 (Pubitemid 36792469)
25. Holden PR, Tugwood JD 1999 Peroxisome proliferator-activated receptor α: role in rodent liver cancer and species differences. J Mol Endocrinol 22:1-8
26. Palmer CN, Hsu MH, Griffin KJ, Raucy JL, Johnson EF 1998 Peroxisome proliferator activated receptor-α expression in human liver. Mol Pharmacol 53:14-22
27. Lambe KG, Woodyatt NJ, Macdonald N, Chevalier S, Roberts RA 1999 Species differences in sequence and activity of the peroxisome proliferator response element (PPRE) within the acyl CoA oxidase gene promoter. Toxicol Lett 110:119-127
28. Bremer J, Osmundsen H 1984 Fatty acid oxidation and its regulation. In: Numa S, ed. Fatty acid metabolism and its regulation. Amsterdam: Elsevier; 113-154
29. Cree MG, Newcomer BR, Read LK, Sheffield-Moore M, Paddon-Jones D, Chinkes D, Aarsland A, Wolfe RR 2007 Plasma triglycerides are not related to tissue lipids and insulin sensitivity in elderly following PPAR-α agonist treatment. Mech Ageing Dev 128:558-565
30. Athyros VG, Mikhailidis DP, Didangelos TP, Giouleme OI, Liberopoulos EN, Karagiannis A, Kakafika AI, Tziomalos K, Burroughs AK, Elisaf MS 2006 Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin 22:873-883
31. Kirk E, Reeds DN, Finck BN, Mayurranjan SM, Mayurranjan MS, Patterson BW, Klein S 2009 Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. Gastroenterology 136:1552-1560
32. Morgan JM, Capuzzi DM, Guyton JR 1998 A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. Am J Cardiol 82:29U-34U; discussion 39U-41U
33. Carlson LA, Oro L 1962 The effect of nicotinic acid on the plasma free fatty acid; demonstration of a metabolic type of sympathicolysis. Acta Med Scand 172:641-645
34. Grundy SM, Mok HY, Zech L, Berman M 1981 Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. J Lipid Res 22:24-36 (Pubitemid 11144704)
35. Ganji SH, Tavintharan S, Zhu D, Xing Y, Kamanna VS, Kashyap ML2004 Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. J Lipid Res 45:1835-1845
36. Jin FY, Kamanna VS, Kashyap ML 1999 Niacin accelerates intracellular ApoB degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells. Arterioscler Thromb Vasc Biol 19:1051-1059
37. Kissebah AH, Alfarsi S, Adams PW, Seed M, Folkard J, Wynn V 1976 Transport kinetics of plasma free fatty acid, very low density lipoprotein triglycerides and apoprotein in patients with endogenous hypertriglyceridaemia: effects of 2,2-dimethyl, 5(2, 5-xylyoxy) valeric acid therapy. Atherosclerosis 24:199-218
38. Kesäniemi YA, Grundy SM 1984 Influence of gemfibrozil and clofibrate on metabolism of cholesterol and plasma triglycerides in man. JAMA 251:2241-2246
39. Packard CJ, Clegg RJ, Dominiczak MH, Lorimer AR, Shepherd J 1986 Effects of bezafibrate on apolipoprotein B metabolism in type III hyperlipoproteinemic subjects. J Lipid Res 27:930-938
40. Shepherd J, Packard CJ, Stewart JM, Atmeh RF, Clark RS, Boag DE, Carr K, Lorimer AR, Ballantyne D, Morgan HG, Veltch Lawrie TD 1984 Apolipoprotein A and B (Sf 100-400) metabolism during bezafibrate therapy in hypertriglyceridemic subjects. J Clin Invest 74:2164-2177
41. Watts GF, Barrett PH, Ji J, Serone AP, Chan DC, Croft KD, Loehrer F, Johnson AG 2003 Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes 52:803-811
42. Bilz S, Wagner S, Schmitz M, Bedynek A, Keller U, Demant T 2004 Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia. J Lipid Res 45:174-185
43. Staels B, Vu-Dac N, Kosykh VA, Saladin R, Fruchart JC, Dallongeville J, Auwerx J 1995 Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J Clin Invest 95:705-712
44. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC 1998 Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98:2088-2093
45. Miettinen TA, Taskinen MR, Pelkonen R, Nikkila EA 1969 Glucose tolerance and plasma insulin in man during acute and chronic administration of nicotinic acid. Acta Med Scand 186:247-253
46. Garg A, Grundy SM 1990 Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA 264:723-726
47. Gibbons LW, Gonzalez V, Gordon N, Grundy S 1995 The prevalence of side effects with regular and sustained-release nicotinic acid. Am J Med 99:378-385
48. Alvarsson M, Grill V 1996 Impact of nicotinic acid treatment on insulin secretion and insulin sensitivity in low and high insulin responders. Scand J Clin Lab Invest 56:563-570
49. Kelly JJ, Lawson JA, Campbell LV, Storlien LH, Jenkins AB, Whitworth JA, O'Sullivan AJ 2000 Effects of nicotinic acid on insulin sensitivity and blood pressure in healthy subjects. J Hum Hypertens 14:567-572
50. Poynten AM, Gan SK, Kriketos AD, O'Sullivan A, Kelly JJ, Ellis BA, Chisholm DJ, Campbell LV 2003 Nicotinic acid-induced insulin resistance is related to increased circulating fatty acids and fat oxidation but not muscle lipid content. Metabolism 52:699-704
51. Chen X, Iqbal N, Boden G 1999 The effects of free fatty acids on gluconeogenesis and glycogenolysis in normal subjects. J Clin Invest 103:365-372 (Pubitemid 29069986)